The safety and efficacy of azimycin 1% eye drops on patients with posterior blepharitis

The safety and efficacy of AZM eye drops on MGD - The efficacy of AZM eye drops on MGD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037715

Enrollment

100

Registered

2019-09-09

Start date

2019-09-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

posterior blepharitis

Interventions

azimycin eyed drop plus warming eyelid warming eyelids

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 18 years old older 2) both gender 3) informed consent available 4) those who were diagnosed with obstructive MGD 5) those who were diagnosed with seborrheic MGD 6) Ocular symptoms 7) lid margin abnormalities 8) plugging

Exclusion criteria

Exclusion criteria: 1) Stevens-Johnson syndrome 2) acute inflammation 3) lid margin abnormalities 4) allergy 5) CL wear 6) Ocular surgery history within 3 monmths 7) systemic dieseases which might interfere with tear function 8) inappropriate charater 9) ocular diseases except cataract and/or refractive error

Design outcomes

Primary

Measure	Time frame
Ocular symptom, lid margin abnormalities, tear film breakup time, lipid layer thickness, non-invasive tear film breakup time, tear osmolarity, meiboscore	—

Countries

Japan

Contacts

Public ContactReiko Arita

Itoh Clinic Ophthalmology

ritoh@za2.so-net.ne.jp+81486865588

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026